Social anxiety disorder and alcohol use disorder co-morbidity in the National Epidemiologic Survey on Alcohol and Related Conditions
- PMID: 20441690
- PMCID: PMC2917264
- DOI: 10.1017/S0033291709991231
Social anxiety disorder and alcohol use disorder co-morbidity in the National Epidemiologic Survey on Alcohol and Related Conditions
Abstract
Background: To assess the prevalence and clinical impact of co-morbid social anxiety disorder (SAD) and alcohol use disorders (AUD, i.e. alcohol abuse and alcohol dependence) in a nationally representative sample of adults in the United States.
Method: Data came from a large representative sample of the US population. Face-to-face interviews of 43093 adults residing in households were conducted during 2001-2002. Diagnoses of mood, anxiety, alcohol and drug use disorders and personality disorders were based on the Alcohol Use Disorder and Associated Disabilities Interview Schedule - DSM-IV version.
Results: Lifetime prevalence of co-morbid AUD and SAD in the general population was 2.4%. SAD was associated with significantly increased rates of alcohol dependence [odds ratio (OR) 2.8] and alcohol abuse (OR 1.2). Among respondents with alcohol dependence, SAD was associated with significantly more mood, anxiety, psychotic and personality disorders. Among respondents with SAD, alcohol dependence and abuse were most strongly associated with more substance use disorders, pathological gambling and antisocial personality disorders. SAD occurred before alcohol dependence in 79.7% of co-morbid cases, but co-morbidity status did not influence age of onset for either disorder. Co-morbid SAD was associated with increased severity of alcohol dependence and abuse. Respondents with co-morbid SAD and alcohol dependence or abuse reported low rates of treatment-seeking.
Conclusions: Co-morbid lifetime AUD and SAD is a prevalent dual diagnosis, associated with substantial rates of additional co-morbidity, but remaining largely untreated. Future research should clarify the etiology of this co-morbid presentation to better identify effective means of intervention.
Conflict of interest statement
None.
References
-
- Bakken K, Landheim AS, Vaglum P. Substance-dependent patients with and without social anxiety disorder: occurrence and clinical differences. A study of a consecutive sample of alcohol-dependent and poly-substance-dependent patients treated in two counties in Norway. Drug and Alcohol Dependence. 2005;80:321–328. - PubMed
-
- Balon R, Mufti R, Arfken CL. A survey of prescribing practices for monoamine oxidase inhibitors. Psychiatric Services. 1999;50:945–947. - PubMed
-
- Blanco C, Antia SX, Liebowitz MR. Pharmacotherapy of social anxiety disorder. Biological Psychiatry. 2002;51:109–120. - PubMed
-
- Blanco C, Schneier FR, Schmidt A, Blanco-Jerez CR, Marshall RD, Sanchez-Lacay A, Liebowitz MR. Pharmacological treatment of social anxiety disorder: a meta-analysis. Depression and Anxiety. 2003;18:29–40. - PubMed
Publication types
MeSH terms
Grants and funding
- MH076051/MH/NIMH NIH HHS/United States
- K02 DA023200/DA/NIDA NIH HHS/United States
- Z99 AA999999/ImNIH/Intramural NIH HHS/United States
- AA00161/AA/NIAAA NIH HHS/United States
- R01 MH076051/MH/NIMH NIH HHS/United States
- DA019606/DA/NIDA NIH HHS/United States
- DA023200/DA/NIDA NIH HHS/United States
- R01 DA020783/DA/NIDA NIH HHS/United States
- R01 DA019606/DA/NIDA NIH HHS/United States
- R01 AA008159/AA/NIAAA NIH HHS/United States
- Z01 AA000449/ImNIH/Intramural NIH HHS/United States
- DA020783/DA/NIDA NIH HHS/United States
- AA08159/AA/NIAAA NIH HHS/United States
LinkOut - more resources
Full Text Sources
Medical
